Combination therapy is another option for overcoming resistance; for example, understanding the mechanism of the MEK inhibitor that causes reactivation of the MAPK pathway, which in turn activates MEK towards the resistance of the BRAF inhibitors (in melanoma), prompted the use of combination therapy consisting of BRAF and MEK inhibitors, which resulted in better clinical outcomes than single therapy. This evidence concerns the gene BRAF and melanoma.